116 related articles for article (PubMed ID: 11423937)
1. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells.
Hombach A; Muche JM; Gerken M; Gellrich S; Heuser C; Pohl C; Sterry W; Abken H
Gene Ther; 2001 Jun; 8(11):891-5. PubMed ID: 11423937
[TBL] [Abstract][Full Text] [Related]
2. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
3. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
4. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
6. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.
Heuser C; Hombach A; Lösch C; Manista K; Abken H
Gene Ther; 2003 Aug; 10(17):1408-19. PubMed ID: 12900755
[TBL] [Abstract][Full Text] [Related]
7. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
8. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
Cheadle EJ; Gilham DE; Thistlethwaite FC; Radford JA; Hawkins RE
Br J Haematol; 2005 May; 129(3):322-32. PubMed ID: 15842655
[TBL] [Abstract][Full Text] [Related]
9. A case of CD30+ nasal natural killer/T-cell lymphoma.
Ferenczi K; Summers P; Aubert P; Cooper B; Meyerson H; Cooper KD; Honda K
Am J Dermatopathol; 2008 Dec; 30(6):567-71. PubMed ID: 19033930
[TBL] [Abstract][Full Text] [Related]
10. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
11. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.
Willemsen RA; Weijtens ME; Ronteltap C; Eshhar Z; Gratama JW; Chames P; Bolhuis RL
Gene Ther; 2000 Aug; 7(16):1369-77. PubMed ID: 10981663
[TBL] [Abstract][Full Text] [Related]
12. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
[TBL] [Abstract][Full Text] [Related]
13. T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.
Hombach A; Heuser C; Gerken M; Fischer B; Lewalter K; Diehl V; Pohl C; Abken H
Gene Ther; 2000 Jun; 7(12):1067-75. PubMed ID: 10871757
[TBL] [Abstract][Full Text] [Related]
14. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
[TBL] [Abstract][Full Text] [Related]
15. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
16. Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta?
Song L; Wang J; Wang R; Yu M; Sun Y; Han G; Li Y; Qian J; Scott DW; Kang Y; Soukhareva N; Shen B
Gene Ther; 2004 Oct; 11(20):1487-96. PubMed ID: 15343360
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification.
Kong YY; Dai B; Kong JC; Zhou XY; Lu HF; Shen L; Du X; Shi DR
Am J Surg Pathol; 2008 Oct; 32(10):1495-502. PubMed ID: 18708940
[TBL] [Abstract][Full Text] [Related]
19. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
20. CD4/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides.
Hodak E; David M; Maron L; Aviram A; Kaganovsky E; Feinmesser M
J Am Acad Dermatol; 2006 Aug; 55(2):276-84. PubMed ID: 16844512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
